Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 6, 2010, Pages 629-633

  Lardone, Ricardo D ^a   Yuki, Nobuhiro ^b   Odaka, Masaaki ^c   Daniotti, Jose L ^a   Irazoqui, Fernando J ^a   Nores, Gustavo A ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b National Hospital Organization Niigata National Hospital   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; AUTOANTIBODY; DRUG DERIVATIVE; GANGLIOSIDE; GANGLIOSIDE GD1ALPHA; GANGLIOSIDE GM1; GANGLIOSIDE, GD1B; GQ1B GANGLIOSIDE; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN BARRE SYNDROME; HUGHES FUNCTIONAL SCALE; HUMAN; MALE; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; DISABILITY; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; THIN LAYER CHROMATOGRAPHY;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, THIN LAYER; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; G(M1) GANGLIOSIDE; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77953689761     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.183665     Document Type: Article

References (28)

1. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
2. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44.
3. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-35.
4. Hadden RDM, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-65.
5. Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998;44:202-8.
6. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-20.
7. Moyano AL, Comín R, Lardone RD, et al. Validation of a rabbit model of neuropathy induced by immunization with gangliosides. J Neurol Sci 2008;272:110-14.
8. Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996;40:181-7.
9. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-16.
10. Koga M, Yuki N, Hirata K, et al. Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain-Barré syndrome. Neurology 2003;60:1514-18.
11. Jacobs BC, Koga M, van Rijs W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol 2008;194:181-90.
12. GuillaineBarré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-90.
13. Yu RK, Ledeen RW. Gangliosides of human, bovine, and rabbit plasma. J Lipid Res 1972;13:680-6.
14. Watanabe K, Arao Y. A new solvent system for the separation of neutral glycosphingolipids. J Lipid Res 1981;22:1020-4. (Pubitemid 11029365)
15. Mizutamari RK, Wiegandt H, Nores GA. Characterization of anti-ganglioside antibodies present in normal human plasma. J Neuroimmunol 1994;50:215-20.
16. Nores GA, Mizutamari RK, Kremer DM. Chromatographic tank designed to obtain highly reproducible high-performance thin-layer chromatograms of gangliosides and neutral glycosphingolipids. J Chromatogr A 1994;686:155-7.
17. Comín R, Yuki N, Lopez PH, et al. High affinity of anti-GM1 antibodies is associated with disease onset in experimental neuropathy. J Neurosci Res 2006;84:1085-90.
18. Crespo PM, Zurita AR, Daniotti JL. Effect of gangliosides on the distribution of a glycosylphosphatidylinositol-anchored protein in plasma membrane from Chinese hamster ovary-K1 cells. J Biol Chem 2002;277:44731-9.
19. Lardone RD, Alaniz ME, Irazoqui FJ, et al. Unusual presence of anti-GM1 IgG-antibodies in a healthy individual, and their possible involvement in the origin of disease-associated anti-GM1 antibodies. J Neuroimmunol 2006;173:174-9.
20. Ravichandra B, Joshi PG. Regulation of transmembrane signaling by ganglioside GM1: interaction of anti-GM1 with Neuro2a cells. J Neurochem 1999;73:557-67.
21. Mizutamari RK, Kremer LJ, Basile EA, et al. Anti-GM1 ganglioside IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy. J Neurosci Res 1998;51:237-42.
22. Lopez PH, Lardone RD, Irazoqui FJ, et al. Variable patterns of anti-GM1 IgM-antibody populations defined by affinity and fine specificity in patients with motor syndromes: evidence for their random origin. J Neuroimmunol 2001;119:131-6.
23. Acquotti D, Fronza G, Ragg E, et al. Three dimensional structure of GD1b and GD1b-monolactone gangliosides in dimethylsulphoxide: a nuclear Overhauser effect investigation supported by molecular dynamics calculations. Chem Phys Lipids 1991;59:107-25.
24. Acquotti D, Poppe L, Dabrowski J, et al. Three-dimensional structure of the oligosaccharide chain of GM1 ganglioside revealed by a distance-mapping procedure: a rotating and laboratory frame nuclear overhauser enhancement investigation of native glycolipid in dimethyl sulfoxide and in water-dodecylphosphocholine solutions. J Am Chem Soc 1990;112:7772-8.
25. Simons K, Vaz WL. Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 2004;33:269-95.
26. Sonnino S, Mauri L, Chigorno V, et al. Gangliosides as components of lipid membrane domains. Glycobiology 2007;17:1R-13R.
27. Prinetti A, Chigorno V, Tettamanti G, et al. Sphingolipid-enriched membrane domains from rat cerebellar granule cells differentiated in culture. A compositional study. J Biol Chem 2000;275:11658-65.
28. Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119:595-610.